ATE384792T1 - Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern - Google Patents

Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern

Info

Publication number
ATE384792T1
ATE384792T1 AT99960397T AT99960397T ATE384792T1 AT E384792 T1 ATE384792 T1 AT E384792T1 AT 99960397 T AT99960397 T AT 99960397T AT 99960397 T AT99960397 T AT 99960397T AT E384792 T1 ATE384792 T1 AT E384792T1
Authority
AT
Austria
Prior art keywords
antibody variants
binding affinities
higher binding
parental antibodies
affinities compared
Prior art date
Application number
AT99960397T
Other languages
English (en)
Inventor
Yvonne Chen
Henry Lowman
Yves Muller
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE384792T1 publication Critical patent/ATE384792T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65H—HANDLING THIN OR FILAMENTARY MATERIAL, e.g. SHEETS, WEBS, CABLES
    • B65H2801/00—Application field
    • B65H2801/87—Photovoltaic element manufacture, e.g. solar panels
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
AT99960397T 1998-11-18 1999-11-16 Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern ATE384792T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10894598P 1998-11-18 1998-11-18

Publications (1)

Publication Number Publication Date
ATE384792T1 true ATE384792T1 (de) 2008-02-15

Family

ID=22324963

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99960397T ATE384792T1 (de) 1998-11-18 1999-11-16 Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern

Country Status (11)

Country Link
US (9) US6632926B1 (de)
EP (1) EP1135498B1 (de)
JP (1) JP2002530081A (de)
AT (1) ATE384792T1 (de)
AU (1) AU1728800A (de)
CA (1) CA2347833A1 (de)
DE (1) DE69938054T2 (de)
DK (1) DK1135498T3 (de)
ES (1) ES2301254T3 (de)
PT (1) PT1135498E (de)
WO (1) WO2000029584A1 (de)

Families Citing this family (191)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962702B2 (en) 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
WO2000037502A2 (en) 1998-12-22 2000-06-29 Genentech, Inc. Vascular endothelial cell growth factor antagonists and uses thereof
US7829064B2 (en) 1999-05-10 2010-11-09 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods
US8119101B2 (en) 1999-05-10 2012-02-21 The Ohio State University Anti-CD74 immunoconjugates and methods of use
US8383081B2 (en) 1999-05-10 2013-02-26 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
EP2289550A3 (de) 2000-01-27 2012-02-15 MedImmune, LLC Neutralisierende Antikörper mit ultrahoher Affinität
US6818216B2 (en) 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
US7179900B2 (en) 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
AU2002231736A1 (en) 2000-12-22 2002-07-08 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Use of repulsive guidance molecule (rgm) and its modulators
US7151164B2 (en) 2002-02-14 2006-12-19 Immunomedics, Inc. Anti-CD20 antibodies and fusion proteins thereof and methods of use
KR20040082421A (ko) * 2002-02-11 2004-09-24 제넨테크, 인크. 빠른 항원 결합 속도를 갖는 항체 변이체
US8287864B2 (en) 2002-02-14 2012-10-16 Immunomedics, Inc. Structural variants of antibodies for improved therapeutic characteristics
US8435529B2 (en) 2002-06-14 2013-05-07 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US8491896B2 (en) * 2002-06-14 2013-07-23 Immunomedics, Inc. Anti-pancreatic cancer antibodies
EP2865688A1 (de) 2002-03-01 2015-04-29 Immunomedics, Inc. Internalisierung von Anti-CD74-Antikörpern und Verfahren zur Verwendung
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
KR101228124B1 (ko) * 2002-06-14 2013-01-31 이뮤노메딕스, 인코오포레이티드 단클론 항체 ｐａｍ4 및 췌장암의 진단 및 치료를 위한이들의 용도
MXPA04012656A (es) * 2002-06-14 2005-08-15 Immunomedics Inc Anticuerpo hpam4 monoclonal humanizado.
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US8821868B2 (en) 2002-06-14 2014-09-02 Immunomedics, Inc. Anti-pancreatic cancer antibodies
US9599619B2 (en) 2002-06-14 2017-03-21 Immunomedics, Inc. Anti-pancreatic cancer antibodies
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
JP5138867B2 (ja) 2002-08-01 2013-02-06 イミューノメディクス、インコーポレイテッド α−フェトタンパク質Ｉｍｍｕ３１抗体および融合タンパク質ならびにその使用方法
US7541440B2 (en) 2002-09-30 2009-06-02 Immunomedics, Inc. Chimeric, human and humanized anti-granulocyte antibodies and methods of use
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
AU2004205684A1 (en) * 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
US9005613B2 (en) 2003-06-16 2015-04-14 Immunomedics, Inc. Anti-mucin antibodies for early detection and treatment of pancreatic cancer
US7109304B2 (en) 2003-07-31 2006-09-19 Immunomedics, Inc. Humanized anti-CD19 antibodies
CN1934255B (zh) 2003-08-27 2012-07-11 奥普索特克公司 用于治疗眼新血管疾病的组合治疗
US8883160B2 (en) 2004-02-13 2014-11-11 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US9550838B2 (en) 2004-02-13 2017-01-24 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
WO2006012361A2 (en) 2004-07-01 2006-02-02 University Of Southern California Genetic markers for predicting disease and treatment outcome
EP1769001A2 (de) * 2004-07-12 2007-04-04 Rapaport Family Institute for Research in the Medical Sciences Verfahren für den nachweis eines phänotyps eines polymorphen proteins
WO2006020114A2 (en) 2004-08-04 2006-02-23 Applied Molecular Evolution, Inc. Variant fc regions
WO2006042177A2 (en) 2004-10-07 2006-04-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
WO2006094192A2 (en) 2005-03-03 2006-09-08 Immunomedics, Inc. Humanized l243 antibodies
JP2008531060A (ja) * 2005-03-04 2008-08-14 バイオジェン・アイデック・エムエイ・インコーポレイテッド 相補性決定残基の合理的改変を介して免疫グロブリン可変領域をヒト化する方法
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
CN101277974A (zh) 2005-09-30 2008-10-01 阿伯特有限及两合公司 排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
EP2674440B1 (de) 2005-12-16 2019-07-03 IBC Pharmaceuticals, Inc. Polyvalente bioaktive anordnungen auf immunglobulinbasis
EP2650306A1 (de) 2006-03-06 2013-10-16 Aeres Biomedical Limited Humanisierte Anti-CD22-Antikörper und ihre Verwendung bei der Behandlung von Krebs, Transplantationen und Autoimmunerkrankungen
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
AU2007287794B2 (en) 2006-08-21 2013-03-28 F. Hoffmann-La Roche Ag Tumor therapy with an anti-VEGF antibody
AU2008205457A1 (en) * 2007-01-18 2008-07-24 University Of Southern California Gene polymorphisms predictive for dual TKI therapy
AU2008247382B2 (en) 2007-05-07 2014-06-05 Medimmune, Llc Anti-ICOS antibodies and their use in treatment of oncology, transplantation and autoimmune disease
EP1997830A1 (de) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV-spezifische Bindemoleküle und Mittel zu ihrer Herstellung
PL2193196T3 (pl) 2007-09-28 2017-07-31 Portola Pharmaceuticals, Inc. Antidotum na czynnik inhibitora XA oraz sposoby jego stosowania
DE102007063295A1 (de) * 2007-12-27 2009-07-02 Natec Gmbh Schneiden einer weichen Lebensmittelmasse
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
EP2347004B1 (de) 2008-06-13 2016-08-10 Rappaport Family Institute for Research in the Medical Sciences Reagentien und verfahren zum nachweis des polymorphen protein haptoglobin
JP6049163B2 (ja) 2008-07-21 2016-12-21 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． 改善された治療上の特徴のための抗体の構造変異体
WO2011091113A2 (en) * 2010-01-22 2011-07-28 Immunomedics, Inc. Detection of early-stage pancreatic adenocarcinoma
JP5933975B2 (ja) 2008-11-12 2016-06-15 メディミューン，エルエルシー 抗体製剤
KR101093717B1 (ko) 2008-11-26 2011-12-19 한국생명공학연구원 Ｖｅｇｆ―특이적인 인간항체
US9079942B2 (en) 2009-02-09 2015-07-14 Epitomics, Inc. CDR-anchored amplification method
PL3604510T3 (pl) 2009-03-30 2025-07-28 Alexion Pharmaceuticals, Inc. Antidota na inhibitory czynnika xa i sposoby ich stosowania
RU2595379C2 (ru) 2009-04-16 2016-08-27 АббВай Биотерапеутикс Инк. АНТИТЕЛА ПРОТИВ TNF-α И ИХ ПРИМЕНЕНИЯ
CA2665956A1 (en) * 2009-05-07 2010-11-07 Samir Patel Combination treatment for ocular diseases
MX2011013781A (es) 2009-06-17 2012-05-29 Abbott Biotherapeutics Corp Anticuerpos anti-vegf y sus usos.
JP6163304B2 (ja) 2009-07-15 2017-07-12 ポートラ ファーマシューティカルズ， インコーポレイテッド 第Ｘａ因子インヒビターの解毒剤の単位用量処方物およびその使用方法
US8293483B2 (en) 2009-09-11 2012-10-23 Epitomics, Inc. Method for identifying lineage-related antibodies
EP3009455A1 (de) 2009-09-16 2016-04-20 Immunomedics Inc. Klasse-i-anti-cea-antikörper und verwendungen davon
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
CN102753580A (zh) 2009-10-28 2012-10-24 亚培生物医疗股份有限公司 抗egfr抗体及其用途
EP3002297B1 (de) * 2009-11-30 2020-04-08 F. Hoffmann-La Roche AG Antikörper zur behandlung und der diagnose slc34a2 (tat211) exprimierender tumore.
KR20120118002A (ko) 2009-12-08 2012-10-25 애보트 게엠베하 운트 콤파니 카게 망막 신경 섬유 층 변성의 치료에 사용하기 위한 ｒｇｍ ａ 단백질에 대한 모노클로날 항체
JP6101489B2 (ja) * 2010-01-28 2017-03-22 アブ バイオサイエンシズ インコーポレイテッド 親和性が低下した抗体およびそれを作製する方法
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
EP2675485A4 (de) 2011-02-15 2014-10-15 Immunomedics Inc Anti-mucin-antikörper zur frühen erkennung und behandlung von pankreaskrebs
RU2013155695A (ru) 2011-06-30 2015-08-10 Дженентек, Инк. Препараты антител против с-мет
WO2013085893A1 (en) 2011-12-05 2013-06-13 Immunomedics, Inc. Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
US9757458B2 (en) 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
MX356933B (es) 2011-12-14 2018-06-20 Abbvie Deutschland Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.
JP6342812B2 (ja) 2011-12-14 2018-06-13 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー 鉄関連障害を診断および治療するための組成物および方法
SG10202006762PA (en) 2012-01-27 2020-08-28 Abbvie Deutschland Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
AU2013234046B2 (en) 2012-03-16 2017-09-07 University Health Network Methods and compositions for modulating Toso activity
US9494597B2 (en) 2012-04-02 2016-11-15 Ab Biosciences, Inc. Human control antibodies and uses therefor
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
CN104704000A (zh) 2012-09-19 2015-06-10 艾伯维生物医疗股份有限公司 识别具有降低免疫原性的抗体的方法
US20140154255A1 (en) 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
CA3177936A1 (en) 2012-12-13 2014-06-19 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
US10206918B2 (en) 2012-12-13 2019-02-19 Immunomedics, Inc. Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
US12310958B2 (en) 2012-12-13 2025-05-27 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US20240139324A1 (en) 2012-12-13 2024-05-02 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
US10413539B2 (en) 2012-12-13 2019-09-17 Immunomedics, Inc. Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
WO2015012904A2 (en) 2012-12-13 2015-01-29 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US10744129B2 (en) 2012-12-13 2020-08-18 Immunomedics, Inc. Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
US9469686B2 (en) 2013-03-15 2016-10-18 Abbott Laboratories Anti-GP73 monoclonal antibodies and methods of obtaining the same
US9452228B2 (en) 2013-04-01 2016-09-27 Immunomedics, Inc. Antibodies reactive with an epitope located in the N-terminal region of MUC5AC comprising cysteine-rich subdomain 2 (Cys2)
JP6581572B2 (ja) 2013-06-07 2019-09-25 デューク ユニバーシティ 補体因子ｈ阻害薬
LT4374873T (lt) 2013-07-12 2025-12-29 Astellas Us Llc Agentas, skirtas panaudoti oftalmologinių būklių gydymui ir profilaktikai
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
CN118005782A (zh) 2013-10-02 2024-05-10 免疫医疗有限责任公司 中和抗甲型流感抗体及其用途
US20150250853A1 (en) 2014-03-07 2015-09-10 University Health Network Methods and compositions for modifying the immune response
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
EP3212668B1 (de) 2014-10-31 2020-10-14 AbbVie Biotherapeutics Inc. Anti-cs1-antikörper und antikörperwirkstoffkonjugate
WO2016133822A1 (en) * 2015-02-19 2016-08-25 Axiomx, Inc. Methods of identifying and validating affinity reagents
CA2978374A1 (en) 2015-03-06 2016-09-15 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
EP3286224A4 (de) 2015-04-22 2018-11-14 Immunomedics, Inc. Isolierung, detektion, diagnose und/oder charakterisierung von zirkulierenden trop-2-positiven krebszellen
EP3303384B1 (de) 2015-06-01 2021-08-25 Medimmune, LLC Neutralisierende anti-influeanza-bindungsmoleküle und verwendungen davon
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
US10287338B2 (en) 2015-07-10 2019-05-14 Miran NERSISSIAN Factor VIII protein compositions and methods of treating of hemophilia A
CA2993009A1 (en) 2015-07-31 2017-02-09 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
EP3365027B1 (de) 2015-10-14 2022-03-30 Research Institute at Nationwide Children's Hospital Hu-spezifische antikörper und deren verwendeng zur hemmung von biofilm
US10188660B2 (en) 2015-11-30 2019-01-29 Abbvie Inc. Anti-huLRRC15 antibody drug conjugates and methods for their use
WO2017095808A1 (en) 2015-11-30 2017-06-08 Abbvie Inc. ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
EP3184544A1 (de) 2015-12-23 2017-06-28 Julius-Maximilians-Universität Würzburg Glycoprotein-v-inhibitoren zur verwendung als koagulansien
CN108712911A (zh) 2015-12-30 2018-10-26 科达制药股份有限公司 抗体及其缀合物
LT3219727T (lt) 2016-03-17 2021-02-10 Tillotts Pharma Ag Anti-tnf alfa antikūnai ir jų funkciniai fragmentai
WO2017158079A1 (en) 2016-03-17 2017-09-21 Numab Innovation Ag Anti-tnfalpha-antibodies and functional fragments thereof
JP6978427B2 (ja) 2016-03-17 2021-12-08 ヌマブ セラピューティクス アクチェンゲゼルシャフト 抗ＴＮＦα抗体とその機能性フラグメント
LT3219726T (lt) 2016-03-17 2021-01-25 Tillotts Pharma Ag Anti-tnf alfa antikūnai ir jų funkciniai fragmentai
EP3430042B1 (de) 2016-03-17 2023-05-24 Numab Innovation AG Anti-tnf-alpha-antikörper und funktionale fragmente davon
RU2725292C2 (ru) 2016-04-27 2020-06-30 Иммьюномедикс, Инк. Эффективность конъюгатов антитела против trop-2 с лекарственным средством sn-38 для терапии рецидивирующих/рефрактерных к ингибиторам контрольной точки опухолей
ES2864150T3 (es) 2016-05-17 2021-10-13 Abbvie Biotherapeutics Inc Conjugados de fármacos con anticuerpos anti-cMet y métodos para su uso
AR108611A1 (es) 2016-05-27 2018-09-05 Abbvie Biotherapeutics Inc Anticuerpos anti-cd40 y sus usos
PE20190562A1 (es) 2016-05-27 2019-04-22 Abbvie Biotherapeutics Inc Proteinas de union biespecificas que se unen a una proteina inmunomoduladora y un antigeno tumoral
EP3464362B1 (de) 2016-05-27 2020-12-09 AbbVie Biotherapeutics Inc. Anti-4-1bb-antikörper und deren verwendungen
HUE051700T2 (hu) 2016-09-14 2021-03-29 Abbvie Biotherapeutics Inc Anti-PD-1 antitestek
JP2019535015A (ja) 2016-10-03 2019-12-05 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ 患者サンプルにおけるｇｆａｐ状況を評価する改善された方法
EP3532498A1 (de) * 2016-10-31 2019-09-04 Hexal AG Antikörperherstellung
WO2018112346A1 (en) 2016-12-15 2018-06-21 Abbvie Biotherapeutics Inc. Anti-ox40 antibodies and their uses
EP3565589A1 (de) 2017-01-04 2019-11-13 Research Institute at Nationwide Children's Hospital Dnabii-impfstoffe und antikörper mit erhöhter aktivität
CN118497192A (zh) * 2017-03-07 2024-08-16 豪夫迈·罗氏有限公司 发现替代性抗原特异性抗体变体的方法
CA3056088A1 (en) 2017-03-15 2018-09-20 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
JP7346300B2 (ja) 2017-03-23 2023-09-19 アボット・ラボラトリーズ 早期バイオマーカーであるユビキチンカルボキシ末端ヒドロラーゼｌ１を使用する、ヒト対象における外傷性脳損傷の程度の診断及び決定の一助となるための方法
CA3050332A1 (en) 2017-03-27 2018-10-04 Immunomedics, Inc. Treatment of trop-2 expressing triple negative breast cancer with sacituzumab govitecan and a rad51 inhibitor
EP3606964A4 (de) 2017-04-03 2020-12-09 Immunomedics, Inc. Subkutane verabreichung von antikörper-arzneimittelkonjugaten zur krebstherapie
TW201836647A (zh) 2017-04-06 2018-10-16 美商艾伯維有限公司 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途
WO2018191531A1 (en) 2017-04-15 2018-10-18 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
WO2018200823A1 (en) 2017-04-28 2018-11-01 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject
US10865238B1 (en) 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
AU2018272054B2 (en) 2017-05-25 2024-10-31 Abbott Laboratories Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
CA3059607A1 (en) 2017-05-30 2018-12-06 Abbott Laboratories Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin i
EP3649474A1 (de) 2017-07-03 2020-05-13 Abbott Laboratories Verbesserte verfahren zur messung von ubiquitin-carboxy-terminalen hydrolase-l1-konzentrationen in blut
EP3687546A4 (de) 2017-09-26 2022-01-26 The Trustees Of The University Of Pennsylvania Zusammensetzungen und verfahren zur behandlung von herzkrankheiten über neuausgerichtete t-zell-immuntherapien
US11016105B2 (en) 2017-12-09 2021-05-25 Abbott Laboratories Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of GFAP and UCH-L1
CA3067057A1 (en) 2017-12-09 2019-06-13 Abbott Laboratories Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1)
JP7437303B2 (ja) 2017-12-29 2024-02-22 アボット・ラボラトリーズ 外傷性脳損傷を診断及び査定するための、新規のバイオマーカー及び方法
BR112020017872A2 (pt) 2018-03-02 2020-12-22 Kodiak Sciences Inc. Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos
WO2019213619A1 (en) 2018-05-04 2019-11-07 Abbott Laboratories Hbv diagnostic, prognostic, and therapeutic methods and products
WO2020016433A1 (en) * 2018-07-20 2020-01-23 Aicuris Gmbh & Co. Kg Methods for screening and identifying agents that inhibit or modulate the nuclear egress complex of herpesviruses
EP3861021B1 (de) 2018-10-05 2025-02-12 Research Institute at Nationwide Children's Hospital Zusammensetzungen und verfahren zur enzymatischen zerstörung bakterieller biofilme
KR20220032066A (ko) 2019-07-08 2022-03-15 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 생물막을 파괴하기 위한 항체 조성물
CA3151438A1 (en) * 2019-09-23 2021-04-01 Ellen PURE Monoclonal antibody against canine fibroblast activation protein that cross-reacts with mouse and human fibroblast activation protein (fap)
CN114746438A (zh) 2019-09-23 2022-07-12 宾夕法尼亚大学董事会 通过靶向成纤维细胞激活蛋白(fap)使肿瘤组织破裂
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
EP4087657A1 (de) 2020-01-08 2022-11-16 Synthis Therapeutics, Inc. Alk5-inhibitoren, konjugate und verwendungen davon
CN115315446A (zh) 2020-03-06 2022-11-08 Go医疗股份有限公司 抗糖-cd44抗体及其用途
CA3175523A1 (en) 2020-04-13 2021-10-21 Antti Virtanen Methods, complexes and kits for detecting or determining an amount of a .beta.-coronavirus antibody in a sample
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
UY39327A (es) 2020-07-16 2022-02-25 Abbvie Inc Anticuerpos anti- alpha-4-beta-7
EP4193149A1 (de) 2020-08-04 2023-06-14 Abbott Laboratories Verbesserte verfahren und kits zum nachweis von sars-cov-2-protein in einer probe
WO2022119841A1 (en) 2020-12-01 2022-06-09 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
WO2023102384A1 (en) 2021-11-30 2023-06-08 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
EP4271998A1 (de) 2020-12-30 2023-11-08 Abbott Laboratories Verfahren zur bestimmung des sars-cov-2-antigens und anti-sars-cov-2-antikörpers in einer probe
WO2022153212A1 (en) 2021-01-13 2022-07-21 Axon Neuroscience Se Antibodies neutralizing sars-cov-2
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
US20250326855A1 (en) 2021-03-05 2025-10-23 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
AU2022279156A1 (en) 2021-05-18 2023-11-02 Abbott Laboratories Methods of evaluating brain injury in a pediatric subject
EP4528280A3 (de) 2021-06-14 2025-07-02 Abbott Laboratories Verfahren zur diagnose oder unterstützung der diagnose von hirnverletzungen durch akustische energie, elektromagnetische energie, überdruckwelle und/oder explosionswind
WO2023014863A1 (en) 2021-08-05 2023-02-09 Go Therapeutics, Inc. Anti-glyco-muc4 antibodies and their uses
EP4392783A1 (de) 2021-08-27 2024-07-03 Abbott Laboratories Verfahren zum nachweis von immunoglobulin g, subklassen 4 (igg4) in einer biologischen probe
CA3230038A1 (en) 2021-08-31 2023-03-09 Hongwei Zhang Methods and systems of diagnosing brain injury
CN118715440A (zh) 2021-08-31 2024-09-27 雅培实验室 诊断脑损伤的方法和系统
US20250066498A1 (en) 2021-09-03 2025-02-27 Go Therapeutics, Inc. Anti-glyco-lamp1 antibodies and their uses
US20250136701A1 (en) 2021-09-03 2025-05-01 Go Therapeutics, Inc. Anti-glyco-cmet antibodies and their uses
AU2022354059A1 (en) 2021-09-30 2024-03-28 Abbott Laboratories Methods and systems of diagnosing brain injury
AU2022413677A1 (en) 2021-12-17 2024-06-27 Abbott Laboratories Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
CA3243074A1 (en) 2022-02-04 2023-08-10 Abbott Laboratories Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
EP4548100A1 (de) 2022-06-29 2025-05-07 Abbott Laboratories Magnetische pflegepunktsysteme und assays zur bestimmung von gfap in biologischen proben
AU2023343487A1 (en) 2022-09-15 2025-03-20 Abbott Laboratories Hbv diagnostic, prognostic, and therapeutic methods and products
WO2024059708A1 (en) 2022-09-15 2024-03-21 Abbott Laboratories Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
WO2024133858A1 (en) 2022-12-22 2024-06-27 Julius-Maximilians-Universität-Würzburg Antibodies for use as coagulants
TW202448960A (zh) 2023-02-07 2024-12-16 美商Ｇｏ治療公司 包括抗醣MUC4抗體及MIC蛋白α1-α2結構域之抗體融合蛋白及其用途
EP4431526A1 (de) 2023-03-16 2024-09-18 Emfret Analytics GmbH & Co. KG Anti-gpvi-antikörper und funktionelle fragmente davon
WO2024211475A1 (en) 2023-04-04 2024-10-10 Abbott Laboratories Use of biomarkers to determine whether a subject has sustained, may have sustained or is suspected of sustaining a subacute acquired brain injury (abi)
WO2024226971A1 (en) 2023-04-28 2024-10-31 Abbott Point Of Care Inc. Improved assays, cartridges, and kits for detection of biomarkers, including brain injury biomarkers
WO2024258967A1 (en) 2023-06-13 2024-12-19 Synthis Therapeutics, Inc. Anti-cd5 antibodies and their uses
WO2025072888A2 (en) 2023-09-28 2025-04-03 Novavax, Inc. Anti-sars-cov-2 spike (s) antibodies and their use in treating covid-19

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931907A (en) 1989-03-30 1990-06-05 Tandem Computers Incorporated Electric module latch assembly
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
CA2125240A1 (en) 1994-06-06 1995-12-07 Su-Jun Deng Synthetic gene libraries
US6010861A (en) * 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
JPH09140386A (ja) * 1995-11-22 1997-06-03 Eiken Chem Co Ltd 甲状腺機能を刺激する活性を持つ抗体
GB9603507D0 (en) 1996-02-20 1996-04-17 Isis Innovation Antibody variants
US6037454A (en) * 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
JP3778945B2 (ja) 1996-11-27 2006-05-24 ジェネンテック・インコーポレーテッド ヒト化抗ＣＤ１１ａ抗体
WO1998023746A1 (en) 1996-11-27 1998-06-04 Genentech, Inc. Antibody mutants
EP1695985B1 (de) 1997-04-07 2011-03-09 Genentech, Inc. Verfahren zur Herstellung humanisierter Antikörper durch randomisierte Mutagenese
EP0973804B1 (de) 1997-04-07 2006-12-27 Genentech, Inc. Anti-vefg antibodies
EP1517921B1 (de) 2002-06-28 2006-06-07 Domantis Limited Dual-specifische liganden mit erhöhter halbwertszeit

Also Published As

Publication number Publication date
US20090010925A1 (en) 2009-01-08
US20110182895A1 (en) 2011-07-28
PT1135498E (pt) 2008-04-30
US6632926B1 (en) 2003-10-14
AU1728800A (en) 2000-06-05
EP1135498B1 (de) 2008-01-23
DE69938054T2 (de) 2009-02-12
US8703133B2 (en) 2014-04-22
EP1135498A1 (de) 2001-09-26
US20150284458A1 (en) 2015-10-08
DE69938054D1 (de) 2008-03-13
JP2002530081A (ja) 2002-09-17
US20190202902A1 (en) 2019-07-04
US20040086502A1 (en) 2004-05-06
DK1135498T3 (da) 2008-05-26
US20100047236A1 (en) 2010-02-25
US20070280931A1 (en) 2007-12-06
ES2301254T3 (es) 2008-06-16
WO2000029584A1 (en) 2000-05-25
CA2347833A1 (en) 2000-05-25
US20170096480A1 (en) 2017-04-06

Similar Documents

Publication Publication Date Title
ATE384792T1 (de) Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern
ATE169058T1 (de) Gegen cd3 gerichtete antikörper
CA2469833A1 (en) Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
CA2212750A1 (en) Humanized antibodies against cd3
ES2171705T3 (es) Complejos de polipeptido-dendrimero.
ATE255906T1 (de) Antikörper gegen cd40
MY145191A (en) Human antibodies that bind human il-12 and methods for producing
BR9507594B1 (pt) anticorpo monoclonal com scfv humanizado, molécula de ácido nucleico recombinante e proteìna recombinante.
WO1999003987A3 (fr) Epitopes du vrs et anticorps les comportant, utiles dans le diagnostic et la therapie
DK1167389T3 (da) Antistoffer mod SEMP1-proteinet, fremgangsmåde til fremstilling heraf samt anvendelse deraf
PT969873E (pt) Hidrato de carbono glicopeptido antigene multiplo, vacina abrangendo o mesmo e seu uso
ATE217086T1 (de) Herstellung von photoprotein konjugaten und verfahren zu ihrer verwendung
NZ305083A (en) Use of cd40 binding proteins (a cd40 ligand or monoclonal antibody that specifically binds to cd40) for stimulating a immune response
WO2001057219A3 (en) Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
EP1326895B8 (de) Monoklonale antikörper gegen hepatitis b virus
ATE131069T1 (de) Composition comprising at least two different antibodies or fragments thereof.
ATE282830T1 (de) Immuntest für human chromogranine a (cga), antikörper, reagenz und dazu geeigneter testsatz
DE59608073D1 (de) Antikörper gegen ein, einen histidin-anteil aufweisendes fusionspolypeptid
EP1950300A3 (de) Antikörpervarianten mit höherer Bindungsaffinität im Vergleich zu verwandten Antikörpern
WO2002076406A3 (en) Antibodies against autoantigens of primary biliary cirrhosis and methods of making and using them
GR3030212T3 (en) Platelet activating factor antagonists.
ATE281471T1 (de) Antikörper-testbesteck zur bestimmung von amylin
BRPI0204599B8 (pt) kit para a detecção simultânea de anticorpo para hcv e antígeno de hcv
SE8705137D0 (sv) Diagnostic method for primary biliary cirrhosis and antibodies suitable to be used in certain versions of the method
ATE352621T1 (de) Antikörpermutante

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1135498

Country of ref document: EP